They assessed the PROTACs on the expression of ERRα and RIPK2 in MCF‐7 breast cancer cells and human THP‐1 monocytes and proved that one PROTAC molecule could be able to mediate the degradation of multiple molecules of RIPK2 via ubiquitin‐proteasomal pathway.43 Furthermore, this hydroxyproline derivatives were further used for the synthesis of HaloPROTACs to target HaloTag7 fusion proteins, by developing chloroalkane‐containing PROTACs against Halo Tag7 fusion protein using the acyl amine moiety for recognizing VHL.44 The gene discussed is RIPK2; the disease is breast carcinoma.